+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients
/PRNewswire/ -- The Lausanne-based team of US investment firm, +ND Capital, today marked its second successful exit in the European biotechnology market as...